December 1, 2005 -- A few years ago, Regeneron Pharmaceuticals had one of the most promising obesity drugs in clinical development - Axokine. Some would have said it was the most promising drug of all, regardless of indication. Now, there is almost no news about the once widely heralded drug. The development history of this anti-obesity drug is an object lesson in why obesity has proved so difficult for biotech and pharma alike...
